|
|
||||||||||
|
J Am Coll Cardiol, 2005; 46:756-760, doi:10.1016/j.jacc.2005.05.050
(Published online 24 August 2005). © 2005 by the American College of Cardiology Foundation |
,







* University Hospital Clinico San Carlos, Madrid, Spain
University Hospital Santa Cruz y San Pablo, Barcelona, Spain
University Hospital Marqués de Valdecilla, Santander, Spain
University Hospital Son Dureta, Palma de Mallorca, Spain
|| University Hospital Infanta-Cristina, Badajoz, Spain
¶ University Hospital Virgen de la Victoria, Malaga, Spain
# University Hospital Carlos Haya, Malaga, Spain
** University Hospital Miguel Servet, Zaragoza, Spain

University Hospital Bellvitge, Barcelona, Spain

University Hospital Vila Nova de Gaia, Porto, Portugal

University Hospital Deceased
Manuscript received January 7, 2005; revised manuscript received April 25, 2005, accepted May 9, 2005.
* Reprint requests and correspondence: Dr. Fernando Alfonso, Cardiología Intervencionista, Hospital Universitario "San Carlos," Plaza de Cristo Rey, Madrid 28040, Spain (Email: falf{at}hotmail.com).
OBJECTIVES: We sought to analyze the very late outcomes of patients treated for in-stent restenosis (ISR) according to treatment allocation and 10 prespecified variables.
BACKGROUND: Long-term results (>2 years) of patients with ISR undergoing repeat coronary interventions are not well established.
METHODS: The Restenosis Intrastent: Balloon angioplasty versus elective Stenting (RIBS) randomized study compared these two strategies in 450 patients with ISR. A detailed systematic protocol was used for late clinical follow-up.
RESULTS: At one-year follow-up (100% of patients), the event-free survival was similar in the two groups (77% stent implantation [ST] arm, 71% balloon angioplasty [BA] arm, log-rank p = 0.19). Additional long-term clinical follow-up (median 4.3 years, range 3 to 5 years) was obtained in 98.6% of patients. During this time 22 additional patients died (9 ST arm, 13 BA arm), 7 suffered a myocardial infarction (3 ST arm, 4 BA arm), 23 required coronary surgery (11 ST arm, 12 BA arm), and 9 underwent repeat coronary interventions (4 ST arm, 5 BA arm) (nonexclusive events). At four years the event-free survival was 69% in the ST arm and 64% in the BA arm (log-rank p = 0.21). Among the 10 prespecified variables, vessel size
3 mm had a major influence on the clinical outcome at four years, with better results in the ST group (hazard ratio 0.51, 95% confidence interval 0.3 to 0.89, p = 0.016).
CONCLUSIONS: Patients with ISR undergoing repeat interventions have a significant event rate at late follow-up. Continued medical surveillance should be continued after one year. Patients with large vessels have a better outcome after repeat stenting.
| ||||||||
This article has been cited by other articles:
![]() |
P. Garg, D. J. Cohen, T. Gaziano, and L. Mauri Balancing the Risks of Restenosis and Stent Thrombosis in Bare-Metal Versus Drug-Eluting Stents: Results of a Decision Analytic Model J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1844 - 1853. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Mishkel, A. L. Moore, S. Markwell, M. C. Shelton, and M. E. Shelton Long-Term Outcomes After Management of Restenosis or Thrombosis of Drug-Eluting Stents J. Am. Coll. Cardiol., January 16, 2007; 49(2): 181 - 184. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |